Breast imaging surveillance after curative treatment for primary non-metastasised breast cancer in non-high-risk women: a systematic review

Jeroen Swinnen1 · Machteld Keupers1 · Julie Soens1 · Matthias Lavens1 · Sandra Postema1 · Chantal Van Ongeval1,2

Received: 9 May 2018 / Revised: 25 September 2018 / Accepted: 2 October 2018 / Published online: 8 November 2018
© The Author(s) 2018

Abstract

Objectives The article summarises the available guidelines on breast imaging surveillance after curative treatment for locoregional breast cancer.

Methods A systematic review of practice guidelines published from 1 January 2007 to 1 January 2017 was performed according to PRISMA methodology. The search was conducted for the EMBASE, MEDLINE, Cochrane and Centre for Reviews and Dissemination databases. On 8 July 2018, all included guidelines were updated to the most recent version.

Results Twenty-one guidelines originating from 18 publishing bodies matched criteria. Publishing bodies consisted of seven governmental institutions, nine medical societies and two mixed collaborations. Publishing boards consisted of six radiological, four oncological, and 11 multidisciplinary teams. Annual bilateral mammography surveillance after breast-conserving therapy was recommended by 17/18 (94.4%) publishing bodies. Annual contralateral mammography surveillance after mastectomy was recommended by 13/18 (72.2%) publishing bodies. Routine use of digital breast tomosynthesis was recommended by 1/18 (5.6%) publishing bodies. Routine breast ultrasound surveillance was recommended by 2/18 (11.1%), deemed optional by 4/18 (22.2%) and not supported by 8/18 (44.4%) publishing bodies. Routine breast magnetic resonance imaging (MRI) surveillance was not recommended by 16/18 (88.9%) publishing bodies, although 6/18 (33.3%) specified subgroups for systematic MRI surveillance.

Conclusions Annual mammography is currently the ‘gold standard’ for breast imaging surveillance. The role of digital breast tomosynthesis (DBT) remains to be further investigated. Most guidelines do not recommend routine breast ultrasound or MRI surveillance, unless indicated by additional risk factors.

Keywords Breast neoplasms · Recurrence · Aftercare · Review · Practice guidelines as topic

Introduction

Breast cancer is the most common malignancy affecting European women. In 2012, 458,337 European women were diagnosed with breast cancer [1]. In Belgium, 88.4% of breast cancers are detected at a locoregional disease stage, allowing curative intention to treat in most patients [2]. As a result, a large survivor population has accumulated over time. In the USA alone, it is estimated there were 3,560,570 female breast cancer survivors as of 1 January 2016, a number expected to rise [3]. As recurrence surveillance poses an increasing workload on imaging centres, use of cost-effective follow-up regimens is essential.

In the absence of strong familial or personal risk factors, breast cancer survivors are considered an intermediate risk subgroup for breast cancer recurrence [4]. The term ‘intermediate risk’ is not well-defined among guidelines, ranging between 15 and 30% risk for recurrence [5–7].

Recurrence can present as a true ipsilateral breast cancer recurrence, a new primary breast cancer in the treated breast, a contralateral breast cancer, an axillary recurrence or distant metastases. Yearly locoregional recurrence (LRR) risk is considered 1.0–1.5%, for at least 15–20 years [4].
Materials and methods

Search strategy

Screening and selection were conducted according to the guidelines for Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [8]. Only the first author searched the MEDLINE, EMBASE, Cochrane Database of Systematic Reviews (CDSR) and Centre for Reviews and Dissemination (CRD) databases for guidelines published from 1 January 2007 to 1 January 2017. The MEDLINE and EMBASE search was performed through the EMBASE search engine and consisted of the following search string: 'breast cancer'/exp. AND ('disease management'/exp. OR 'tumour recurrence'/exp. OR 'evaluation and follow up'/exp) AND 'imaging and display'/exp. All search terms were expanded. Review of the CDSR and CRD databases was performed for the MeSH term: 'breast neoplasms'. The reference sections from all full-text assessed papers were also manually searched.

Selection criteria

Inclusion criteria:
- Practice guideline from a medical society or institutional/governmental body.
- Imaging surveillance after curative treatment for primary non-metastasised breast cancer.
- Journal article, web page, abstract, book section.

Exclusion criteria:
- Male breast cancer.
- High risk for recurrence (≥ 20%), including genetic/familial susceptibility.
- Young breast cancer patients, less than 40 years of age at diagnosis.
- Personal history of B3 lesions (i.e. lobular neoplasia, atypical ductal hyperplasia [ADH], flat epithelial atypia [FEA], papillary lesions, etc.).
- History of chest irradiation.

Data extraction

Data on the following outcomes was extracted only by the first author: publisher; country and nature of the publishing body; guideline target group; month/year published; timing of imaging surveillance onset; frequency of imaging surveillance; timing of screening alteration; recommended imaging continuation after alteration; termination of imaging follow-up; use of mammography after breast-conserving therapy (BCT); use of mammography after mastectomy; use of breast/axillary ultrasound; use of contrast enhanced-magnetic resonance imaging (CE-MRI) and use of other imaging modalities.

Results

PRISMA flow diagram

A PRISMA flow diagram depicts the first author’s article search and selection process (Fig. 1). Out of 7,457 search results, including 151 duplicates, 134 abstracts were evaluated. After full text review of 59 articles and inclusion of 6 updated guidelines, 21 met the inclusion criteria. Of 44 articles rejected, 16 articles did not discuss imaging surveillance after breast cancer, 13 articles discussed imaging follow-up without providing a consensus-based clinical guideline and one article was identified as a summary of an included guideline. For six articles, the content did not correspond to the title. Furthermore, eight articles were excluded because a more recent guideline from the same publishing body was included.

Characteristics of studies

The 21 included practice guidelines, as described in Table 1, were provided by 18 publishing bodies from the following countries: four from the United States of America (USA), four from Canada, two from the United Kingdom (UK) and one from France, Australia, New Zealand, Germany, Italy, Switzerland, Belgium, and The Netherlands [4, 6, 9–27]. As three guidelines were published by the American College of Radiology (ACR) and two by the Haute Autorité de Santé (HAS), complementary data from these guidelines were combined in Tables 2 and 3, with no conflicting recommendations encountered [6, 9, 10, 19, 20]. Publishing bodies were seven governmental institutions, nine medical societies and two bodies of mixed nature. The British Columbia Ministry of Health-British Columbia Medical Association (BCMH-BCMA) and Nationaal Borstkanker Overleg Nederland-Knowledge Institute of Medical Specialists (NABON-KIMS) guidelines were provided by a governmental body, but received endorsement from their respective medical societies before publishing [14, 22]. Recommendations were made on six guidelines by a radiological, four by an oncological, and 11 by a multidisciplinary board (Table 1). On 8 July 2018, all included guidelines were updated to the most recent version.

Imaging onset, frequency and termination

If a patient did not receive adjuvant radiation therapy, 5/18 (27.8%) publishing bodies recommended imaging onset at 12 months after diagnosis. The NABON and GISMa-ICBR/SIRM guidelines recommended onset 12 months after the last
pre-operative imaging and after treatment termination respectively. Specification of imaging onset was not provided by 10/18 (55.6%) publishing bodies.

If a patient received adjuvant radiation therapy, 6/18 (33.3%) publishing bodies recommended onset of breast imaging starting at 6 months after completion of radiation therapy. The NCCN and ACR guidelines recommended onset of imaging between 6–12 months post-radiation. The DKG-DGGG guideline stated that onset should be adjusted to the type of surgery and/or radiation therapy, without further specifying a time frame. Specification of post-radiation imaging onset was not provided by 9/18 (50.0%) publishing bodies.

Annual breast imaging surveillance was recommended by 17/18 (94.4%) publishing bodies. In addition, 2/18 (11.1%) guidelines recommended more frequent early follow-up, if postoperative changes impeded recurrence detection. The GISMa-ICBR/SIRM guideline did not provide a recommended screening frequency, but briefly mentioned both annual and biannual imaging follow-up.

Alteration of annual imaging frequency after a certain patient age and/or imaging period, was not discussed by 13/18 (72.2%) publishing bodies. The NICE and NABON guidelines recommended annual imaging for women younger than 50 and 60 years of age respectively. For older women, annual mammography for 5 consecutive years was recommended, before returning to the national breast screening frequency. The Royal College of Radiologists (RCR) recommended annual imaging continuation until 50 years of age, with frequency afterwards varying between 1 and 3 years for ipsilateral and 2–3 years for contralateral surveillance. The Belgian Health Care Knowlegde Center (KCE) stated annual imaging should continue at least 10 years. The ACR recognised patients could return to routine screening at some point, dependent upon institutional protocol.

Termination of breast imaging surveillance was not discussed by 13/18 (72.2%) publishing bodies. The GISMa-ICBR/SIRM and NABON guidelines stated imaging termination should be considered after 74 and 75 years of age respectively. The RCR stated explicitly, no evidence-based recommendation on the timing of surveillance termination could be made at publication. However, the RCR did not recommend routine imaging surveillance of the contralateral breast after the age of 75 years, while routine ipsilateral surveillance should be stopped depending on co-morbidities. The HAS guideline stated imaging surveillance should be re-evaluated every 5 years. The CCMB discouraged imaging screening if life expectancy was less than 5 years.
Following breast-conservative surgery, bilateral mammography was advised by all 18/18 (100%) publishing bodies. If the patient received mastectomy surgery, 13/18 (72.2%) recommended only contralateral mammography follow-up. One exception was made by the RCR, for autologous reconstructions with a high risk for recurrence. Follow-up after mastectomy was not specified by 5/18 (27.8%) publishing bodies.

Routine ultrasound surveillance was not recommended by 8/18 (44.4%) publishing bodies. Furthermore, 4/18 (22.2%) publishing bodies did not recommend routine use, but recognised breast ultrasound as an appropriate screening tool for patients with additional risk factors, such as young age or dense breasts. The only 2/18 (11.1%) publishing bodies that recommended routine use of breast ultrasound, were ESMO and DKG-DGGG, the latter specifically including the axilla.

Routine breast MRI surveillance, with or without intravenous contrast, was not recommended by 10/18 (55.6%) publishing bodies. In the presence of inconclusive findings or additional individual risk factors, 6/18 (27.8%) publishing bodies recognised breast MRI surveillance as a supplemental tool.
Table 2  Recommendations on onset, frequency, intermediate frequency alteration and termination of breast imaging surveillance

| Guideline       | Imaging onset                  | Frequency       | Alteration of annual screening frequency                                                                 | Screening frequency after alteration | Termination of imaging follow-up |
|-----------------|--------------------------------|-----------------|------------------------------------------------------------------------------------------------------------|--------------------------------------|----------------------------------|
| ACR             | 6–12 months after RT           | Annual          | May be returned to routine screening at some point, dependent upon institutional protocol                    | Return to routine breast cancer screening | NS                               |
| ACS-ASCO        | NS                             | Annual          | NS                                                                                                         | NS                                   | NS                               |
| ASCO            | ≥ 6 months after RT            | Annual          | NS                                                                                                         | NS                                   | NS                               |
| AHS             | 12 months after diagnosis or ≥ 6 months after RT | Annual          | NS                                                                                                         | NS                                   | NS                               |
| BCHM-BCMA       | ≥ 6 months after RT            | Annual          | NS                                                                                                         | NS                                   | NS                               |
| CAR             | NS                             | Annual          | NS                                                                                                         | NS                                   | NS                               |
| CCMB            | 12 months after diagnosis or ≥ 6 months after RT | Annual          | NS                                                                                                         | NS                                   | NS                               |
| DKG-DGGG        | Dependent on type of RT and/or surgery | Annual          | NS                                                                                                         | NS                                   | NS                               |
| ESMO            | NS                             | Annual          | NS                                                                                                         | NS                                   | NS                               |
| GISMa-ICBR/SIRM | 12 months after treatment      | NS, but mentions both annual and biannual                                                             | NS                                                                                                         | NS                                   | NS                               |
| HAS             | ≥ 12 months after diagnosis or ≥ 6 months after RT | Annual          | NS                                                                                                         | NS                                   | Re-evaluate every 5 years        |
| KCE             | NS                             | Annual          | Annual at least 10 years                                                                                   | NS                                   | NS                               |
| NABON           | ± 12 months after the last pre-operative mammography/MRI | Annual          | After 5 years, if ≥ 60 years old at time of follow-up                                                        | Mammmography every 2 years          | Consider stop if > 75 years old |
| NBOCC           | 12 months after diagnosis      | Annual          | NS                                                                                                         | NS                                   | NS                               |
| NCCN            | 6–12 months after RT           | Annual          | NS                                                                                                         | NS                                   | NS                               |
| NICE            | NS                             | Annual          | After 5 years, if ≥ NHSBSP/BTWP screening age                                                               | NS                                   | NS                               |
| NZGG            | 12 months after diagnosis or 6 months after RT | Every 6–12 months. Annual if stable mammographic findings | NS                                                                                                         | NS                                   | NS                               |
| RCR             | NS                             | Annual          | Reconsider if 50 years old                                                                                  | CL: mammography every 2–3 years IL: mammography every 1–3 years | CL: 75 years old IL: if co-morbidities make detection unhelpful |

NS not specified, NHSBSP/BTWP National Health Service Breast Screening Program/Breast Test Wales Screening Programme. For other abbreviations see Table 1

*More frequently if recommended by the radiologist

a After mastectomy, coordinated by the national breast screening programme. After breast-conserving therapy, coordinated by general practitioner

b The duration of the follow-up should be determined in consultation between the physician and patient
imaging tool. The ACR recommended systematic use of annual contrast-enhanced MRI in two subgroups of female breast cancer survivors: women with dense breasts and women diagnosed before the age of 50. For these women, MRI should not replace mammography or DBT, but should be used as an adjunct examination. Breast MRI surveillance was not specified by 2/18 (11.1%) publishing bodies.

Only the ACR recognised DBT as a surveillance tool for breast cancer survivors [24]. The ACR considered DBT, with accompanying planar or synthesised 2-D images, an equal modality to diagnostic digital mammography. A brief mention of DBT as supplemental imaging modality was provided by the GISMa-ICBR/SIRM guideline, however without further elaboration or recommendation. Use of DBT or other breast imaging modalities for breast cancer surveillance is summarised in Table 3.

Table 3  Recommendations on modalities for breast imaging surveillance

| Guideline           | Mammography | Ultrasound | (CE-)MRI | Other |
|---------------------|-------------|------------|----------|-------|
|                     | BCT Mastectomy | Optional, especially for dense breasts | Recommended for dense breast tissue | DBT* |
| ACR                 | BL CL       | Optional, especially for dense breasts | Recommended for dense breast tissue | DBT* |
| ACS-ASCO            | BL CL       | NR         | NR       | NR    |
| ASCO                | BL NS       | NR         | NR       | NR    |
| AHS                 | BL CL       | NR         | NR       | NR    |
| BCMH-BCMA           | BL CL       | NR         | NR       | NR    |
| CAR                 | BL NS       | NS         | NS       | NS    |
| CCMB                | BL CL       | NR         | NR       | NR    |
| DKG-DGGG            | BL CL       | If quality-assured, should be added for breasts and axilla | May play an additional role in the differentiation of scar vs recurrence | NR |
| ESMO                | BL CL       | BL/CL      | NR       | Brief mention of DBT as a supplemental investigation, without further elaboration or recommendation |
| GISMa-ICBR/SIRM     | BL NS       | NS         | NR       |       |
| HAS                 | BL CL       | May be associated | NR       | NR* |
| KCE                 | BL NS       | With or without | Initial BC not seen on other imaging | NR |
| NABON-KIMS          | BL CL       | NS         | May play an additional role in: | NR |
|                     |             |            | - differentiation scar vs recurrence |       |
|                     |             |            | - BC not visible on mammography |       |
|                     |             |            | - autologous breast reconstructions |       |
| NBOCC               | BL CL       | If indicated on clinical or radiological grounds, including: | Specific high-risk subgroups | NR |
|                     |             | - young women | |       |
|                     |             | - dense breasts | |       |
|                     |             | - initial breast cancer undetectable by mammography | |       |
| NCCN                | BL CL       | NR         | NR       | NRd |
| NICE                | BL CL       | NR         | NR       | NR    |
| NZGG                | BL NS       | NS         | NS       | NR    |
| RCR                 | BL CL*      | NR         | NR       | NS    |

NS not specified, NR not recommended, RT radiation therapy, LRT locoregional therapy, BC breast cancer, BCT breast-conserving therapy, DBT digital breast tomosynthesis, IL ipsilateral, CL contralateral, BL bilateral, (CE-)MRI (contrast-enhanced) magnetic resonance imaging. For other abbreviations see Table 1

*Diagnostic digital breast tomosynthesis (DBT) received identical appropriateness score (9/9) and relative radiation level rating (2/3) as diagnostic mammography. For intermediate-risk women, breast mammography or DBT (with accompanying planar or synthesised 2-D images) is recommended

b For patients who take tamoxifen, an annual gynaecological examination is recommended, possibly with a gynaecological ultrasound

c For patients who take an aromatase inhibitor, regular bone density evaluation is recommended

d Monitoring of bone health with a bone mineral density determination at baseline and periodically thereafter is advised for women on aromatase inhibitors or women who experience ovarian failure secondary to treatment

e Also ipsilateral, if autologous reconstruction with high recurrence risk
imaging modalities was not recommended by 14/18 (83.3%) publishing bodies and not discussed by 2/18 (11.1%) publishing bodies.

Discussion

Onset of imaging surveillance

During the first 6–12 months after surgical excision and/or adjuvant radiation therapy (RT), post-surgical and post-radiation changes are most likely to occur [28]. Initial radiological differentiation between scar formation, altered tissue and true recurrence can therefore be challenging. Furthermore, mammography yield during the first months after surgery/radiation therapy appears to be low [29, 30]. Seven publishing bodies therefore recommended a 12-month imaging delay following diagnosis, final pre-operative imaging or treatment. Likewise, six publishing bodies recommended a 6-month and two bodies a 6–12 month imaging delay after radiation therapy (Table 2).

Screening frequency

Annual breast imaging surveillance was recommended by all included publishing bodies, except for the GISMa-ICBR/SIRM guideline, which did not specify annual or biannual imaging screening. In a recent health technology assessment (HTA), a 12–24 months imaging interval appeared to be most beneficial overall, although women with the lowest recurrence of risk seemed to have the greatest net benefit from a triennial interval. This study also implied that recurrence risk stratification should be considered, to determine the optimal imaging interval [31]. To our knowledge, no prospective study comparing annual to alternative screening frequencies is currently available [4]. A large multi-centre randomised controlled trial (RCT) is currently enrolling, which will compare annual to biennial mammography after BCT and annual to triennial mammography after mastectomy [32].

Although debated, early semi-annual breast surveillance has been found beneficial over annual follow-up [33]. Stabilisation of postoperative mammographic findings, generally takes place 2–3 years after BCT [28]. Two publishing bodies therefore recommended an early 6–12 months imaging interval, if early postoperative changes interfered with recurrence detection.

Early alteration of annual screening

Optimal duration and frequency of imaging surveillance is a common concern among breast cancer survivors. In a survey by de Bock et al. [34], 56 out of 84 breast cancer survivors responded that they would like to attend lifelong follow-up. Due to paucity of evidence, there is currently no consensus among guidelines for if or when annual imaging should be terminated.

The NICE and NABON guidelines limited the annual screening interval to the first 5 years post-diagnosis, as the rate of true ipsilateral recurrences should peak during this time window [22, 25]. Some authors, however, argue that the combined recurrence rate of true recurrences and new ipsilateral/contralateral breast malignancies, remains steady for at least 20 years [4, 35].

Termination of imaging surveillance

As the RCR guideline stated, no evidence-based recommendation on the timing of surveillance termination can currently be made [27]. The limited number of recommendations identified, therefore vary widely (Table 2).

Mammography after breast-conserving therapy (BCT)

All included practice guidelines recommended bilateral mammography surveillance after BCT. Nonetheless, supporting evidence is limited to observational and retrospective findings. Sensitivity ranges between 63.5 and 67%, which is significantly lower than for matched screenings without a personal history of breast cancer, ranging between 73.5 and 76.5% [15–17]. There is no significant difference between ipsilateral and contralateral sensitivity, while specificity ranges 98.2–98.4% [15]. A survival benefit from surveillance mammography in asymptomatic breast cancer survivors has been suggested by multiple observational studies [36]. However, estimated hazard ratio for asymptomatic relative to symptomatic/clinical detection varies widely, ranging between 0.10 and 0.86 [36]. In a single-centre retrospective analysis of 1,044 patients, detection of asymptomatic recurrence improved relative survival between 27 and 47% [37].

Mammography after mastectomy

None of the included guidelines recommended routine ipsilateral imaging follow-up after mastectomy surgery, with or without reconstruction. This included both implant as well as autologous reconstructive procedures. The RCR was the only body to make an additional recommendation for ipsilateral surveillance in case of an autologous reconstruction with a high risk for recurrence (Table 3). Following a non-reconstructive mastectomy, recurrence should theoretically be limited to the (sub)cutaneous tissue, allowing simple detection from rigorous clinical examination [38]. For implant-based reconstructions, silicone pockets are generally placed behind the pectoralis major muscle, displacing the entire mastectomy site anteriorly. Recurrence should therefore present as superficial and be easily appreciable on clinical examination.
In case of an autologous reconstruction, the reconstructed breast comes on top of the major pectoral muscle and is covered by transplanted skin. The true resection margin therefore remains deep to the reconstructed breast [38]. Nonetheless, Lee et al. [39] concluded from a retrospective cohort of 554 mammograms in 265 women who underwent TRAM flap reconstruction that routine mammographic surveillance of all autologous reconstructed breasts was not likely to be beneficial.

**Digital breast tomosynthesis (DBT)**

Supplementary or equivalent use of DBT in the general population screening has received much attention in recent literature. Evidence has grown in recent years that DBT addition increases cancer detection and reduces false-positive, recall and interval cancer rates, compared to mammography alone [10]. The ACR therefore recommended DBT with accompanying planar or synthesised 2-D images as a screening tool for breast cancer survivors [6]. However, very few studies have investigated the role of DBT in breast cancer recurrence surveillance [40]. In a prospective single-centre study including 618 women with a personal history of breast cancer, addition of DBT significantly reduced the rate of indeterminate findings from 13.1 to 10.5% \( (p = 0.018) \) [41]. Nonetheless, concerns remain regarding longer interpretation times, additional dose and effectiveness of 2-D reconstructions [40]. As new evidence emerges, guidelines are likely to undergo revision.

**Ultrasound**

As routine ancillary ultrasound surveillance remains debated, most publishing bodies do not recommend routine ultrasound surveillance (Table 3). In the prospective multicentre ACRIN 6666 trial, which included a subgroup of 1,426 female breast cancer survivors with heterogeneously dense breast tissue in at least one quadrant, women were randomised to a sequence of three yearly screenings with mammography alone or a combination of mammography and ultrasound [42]. Subgroup analysis of women with a personal history of breast cancer was included in the supplementary online content. Addition of ultrasound significantly \( (p < 0.001) \) increased cancer detection from 8.2/1,000 to 12.5/1,000 screens and sensitivity from 55.9 to 84.7%. However, specificity and PPV3 were significantly \( (p < 0.001) \) inferior after the addition of ultrasound [42].

**MRI**

Breast MRI screening, without or with intravenous contrast, is generally limited to high-risk women. Estimated risk to include women in a high-risk screening programme varies widely among guidelines, ranging between 20 and 30% [5–7, 43]. Most women with a personal history of breast cancer, but without explicit familial/genetic/iatrogenic risk of recurrence, are currently considered an intermediate risk subgroup [10]. Breast MRI screening has shown to be cost-effective for high-risk women, but is still debated for intermediate-risk women, although there is growing literature considering this topic.

Additional cancer yield for MRI recurrence surveillance varies between 9.9 to 28.8 cancers/1,000 examinations, but has been reaffirmed in multiple retrospective single-centre studies [40, 44]. In 2016, a retrospective single-centre study compared 915 primary MRI screenings of female breast cancer survivors without additional risk factors to MRI screenings of 606 non-affected women with high genetic or familial risk [45]. The study concluded that specificity was significantly higher \( (94.0 \text{ vs } 86.0\%, \ p < 0.001) \) in the survivor compared to the genetic/familial risk group. Furthermore, the false-positive rate \( (12.3 \text{ vs } 21.6\%, \ p < 0.001) \) was significantly lower in the survivor subgroup. Sensitivity \( (80.0 \text{ vs } 78.6\%, \ p > 0.99) \) and cancer yield \( (1.7 \text{ vs } 1.8\%, \ p > 0.99) \) did not differ statistically [45].

MRI surveillance has been suggested to be more beneficial for young breast cancer survivors, particularly those younger than 50 years of age at diagnosis [10, 46]. Women with other recurrence risk factors, such as dense breasts or a first-degree family history, might also benefit more from MRI screening [47]. In its most recent update, the ACR therefore recommended routine annual contrast-enhanced breast MRI surveillance for two subgroups of women with a personal history of breast cancer: women with dense breasts and women with a breast cancer diagnosis before the age of 50. According to the authors, this combination of risk factors is likely to exceed a life-time risk of 20%, justifying annual MRI surveillance as indicated by high-risk screening guidelines [10]. Risk stratification according to patient, treatment and tumour characteristics, will likely transform the selection of imaging modalities and intensity in the near future [48].

**Study limitations**

The setup of our study has several limitations worth noting. First of all, the article search and data extraction was performed only by the first author, so lack of double reading could lead to the exclusion of guidelines or data. Secondly, we included only articles with an English-language abstract, although we did not exclude non-English-language articles. Thirdly, we did not use a methodological quality assessment tool to assess the quality of the included practice guidelines. 

**Conclusions**

Annual surveillance mammography is considered standard practice among guidelines, based on retrospective findings of reduced mortality. Imaging surveillance should not
commence earlier than 12 months after diagnosis or 6 months after completion of radiation therapy. No consensus was found regarding intermediate frequency alteration or termination of surveillance.

Although performance of DBT in a surveillance setting is still unclear, the ACR is the first publishing body to recognise DBT as an alternative for breast mammography surveillance. As new evidence emerges, guidelines are likely to undergo revision.

Routine ultrasound surveillance is not recommended by most guidelines. However, optional surveillance is recognised for some subgroups, such as young women or women with dense breasts. Routine breast MRI surveillance is also not recommended, unless women carry additional risk factors, indicating a lifetime recurrence risk > 20%.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403
2. Belgian Cancer Registry (2016) Incidence fact sheet female breast cancer ICD10: C50 Belgium 2014. Stichting Kankerregister, Brussels. Available via http://www.kankerregister.org/media/docs/Incidencefactsheets/Incidence_Fact_Sheet_FemaleBreastCancer_2014.pdf. Accessed 2 February 2018
3. Miller KD, Siegel RL, Lin CC et al (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66:271–289
4. Bucchi L, Belli P, Benelli E et al (2016) Recommendations for breast imaging follow-up of women with a previous history of breast cancer: position paper from the Italian Group for Mammography Screening (GISMa) and the Italian College of Breast Radiologists (ICBR) by SIRM. Radiol Med 121:891–896
5. Saslow D, Boetes C, Burke W et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75–89
6. Mainiero MB, Moy L, Baron P et al (2017) ACR appropriateness criteria® breast cancer screening. J Am Coll Radiol 14:S383–s390
7. National Institute for Health and Care Excellence (NICE) (2017) NICE clinical guideline 164 [CG164]: Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. National Institute for Health and Care Excellence (NICE), Manchester. Available via https://www.nice.org.uk/guidance/cg164. Accessed 22 July 2018
8. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269 w264
9. Moy L, Bailey L, D’Orsi C et al (2017) ACR appropriateness criteria® stage I breast cancer: initial workup and surveillance for local recurrence and distant metastases in asymptomatic women. J Am Coll Radiol 14:S282–s292
10. Monticciolo DL, Newell MS, Moy L, Niell B, Monseses B, Sickle EA (2018) Breast cancer screening in women at higher-than-average risk: recommendations from the ACR. J Am Coll Radiol 15:408–414
11. Runowicz CD, Leach CR, Henry NL et al (2016) American Cancer Society/American Society of Clinical Oncology breast cancer surveillance: a guideline update. CA Cancer J Clin 66:43–73
12. Khatceressian JL, Hurley P, Bantug E et al (2013) Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31:961–965
13. Alberta Provincial Breast Tumour Team (2013) Follow-up care for early-stage breast cancer. Alberta Health Services, Edmonton. Available via https://www.albertahealthservices.ca/assets/info hp/cancer/if-hp-cancer-guide-br013-early-stage-follow-up.pdf. Accessed 8 July 2018
14. Guidelines and Protocols Advisory Committee British Columbia Ministry of Health (2013) Breast cancer: management and follow-up. Guidelines and protocols advisory committee British Columbia Ministry of Health, Victoria. Available via http://www2.gov.bc.ca/assets/gov/health/practitioner-pro/bc-guidelines/brcancer.pdf. Accessed 8 July 2018
15. Canadian Association of Radiologists (2012) Diagnostic imaging referral guidelines: section M: breast disease. Canadian Association of Radiologists. Available via https://car.ca/wp-content/uploads/Breast-disease.pdf. Accessed 8 July 2018
16. CancerCareManitoba (2017) Surveillance Recommendations and Checklist 2016: Breast Cancer. CancerCareManitoba, Winnipeg. Available via https://www.cancercare.mb.ca/export/sites/default/For-Health-Professionals/galleries/files/follow-up-care-files/breast/Breast_FollowUp_Guidelines-Not_Receiving_Hormone_Therapy_Jan_2017.pdf. Accessed 8 July 2018
17. Onkologie L (2017) Leitlinienreport zur S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms Version 4.0. Leitlinienprogramm Onkologie, Berlin. Available via https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/LL_Mammakarzinom_Langversion_4.0.pdf. Accessed 8 July 2018
18. Senkus E, Kyriakides S, Ohno S et al (2015) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:v8–v30
19. Haute Autorité de Santé (2010) Guide ALD 30: Cancer du sein. Haute Autorité de Santé, Saint-Denis. Available via http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-02/ald_30_ g_m_ksein_vd.pdf. Accessed 8 July 2018
20. Haute Autorité de Santé (2015) Dépistage et prévention du cancer du sein. Haute Autorité de Santé, Saint-Denis. Available via http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-04/refecs_k_du_sein_vf.pdf. Accessed 8 July 2018
21. Wildiers H, Stordeur S, Vlayen J et al (2013) Breast cancer in women: diagnosis, treatment and follow-up. Belgian Health Care Knowledge Centre (KCE), Brussels. Available via https://kce.fgov.be/sites/default/files/atoms/files/KCE_143_Breast_cancer_0.pdf. Accessed 8 July 2018
22. Nationaal Borstkanker Overleg Nederland (2012) The National Breast Cancer Guideline. Knowledge Institute of Medical Specialists, Utrecht. Available via https://richtlijnendatabase.nl/en/richtlijn/breast_cancer/aftercare_and_follow-up.html. Accessed 8 July 2018
23. National Breast and Ovarian Cancer Centre (2010) Recommendations for follow-up of women with early breast cancer: a clinical practice guideline. National Breast and Ovarian Cancer Centre, Surry Hills. Available via https://canceraustralia.gov.au/publications-and-resources/cancer-australia-publications/recommendations-follow-women-early-breast-cancer-0. Accessed 8 July 2018
24. Gradishar WJ, Anderson BO, Aft R et al (2018) National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2018 Breast Cancer. National Comprehensive Cancer Network, Fort Washington. Available via https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 8 July 2018

25. National Institute for Health and Care Excellence (NICE) (2013) Guidance on screening and symptomatic breast imaging, 3rd edn. The Royal College of Radiologists, London. Available via https://www.rcr.ac.uk/system/files/publication/field_publication_files/BFCR%2813%295 Breast.pdf. Accessed 8 July 2018

26. New Zealand Guidelines Group (2009) Management of early breast cancer. New Zealand Guidelines Group, Wellington. Available via https://www.health.govt.nz/system/files/documents/publications/mgmt-of-early-breast-cancer-aug09.pdf. Accessed 8 July 2018

27. The Royal College of Radiologists (2013) Guidance on screening and symptomatic breast imaging. Clinical Oncology 35: S53–S62

28. Lin K, Eradat J, Mehta NH et al (2008) Is a short-interval mammography necessary after breast conservation therapy? Int J Radiat Oncol Biol Phys 72:1041–1047

29. Hymas RV, Gaffney DK, Parkinson BT, Belpin TW, Sause WT (2012) Is short-interval mammography necessary after breast conservation surgery and radiation treatment in breast cancer patients? Int J Radiat Oncol Biol Phys 83:519–524

30. Robertson C, Arcot Ragupathy SK, Boachie C et al (2011) The clinical effectiveness and cost-effectiveness of different surveillance mammmogram regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation. Health Technol Assess 15(S):v–vi 1-322

31. Dunn JA, Donnelly PK, Marshall A et al (2014) Follow-up in early breast cancer—a surgical and radiological perceptive. Clin Oncol (R Coll Radiol) 26:625–629

32. Arasu VA, Joe BN, Lvoff NM et al (2012) Benefit of semiannual ipsilateral mammographic surveillance following breast conservation therapy. Radiology 264:371–377

33. de Bock GH, Bonnema J, Zwaan RE, van de Velde CJ, Kievit J, Stiggelbout AM (2004) Patient’s needs and preferences in routine follow-up after treatment for breast cancer. Br J Cancer 90:1144–1150

34. Montgomery DA, Krupa K, Jack WJ et al (2007) Changing pattern of the detection of locoregional relapse in breast cancer: the Edinburgh experience. Br J Cancer 96:1802–1807

35. Houssami N, Ciatto S (2010) Mammographic surveillance in women with a personal history of breast cancer: how effective? How accurate? How effective? Breast 19:439–445

36. Gradishar WJ, Anderson BO, Aft R et al (2018) Early detection of second breast cancers improves prognosis in breast cancer survivors. Ann Oncol 20:1505–1510

37. Freyvogel M, Padia S, Larson K et al (2014) Screening mammography following autologous breast reconstruction: an unnecessary effort. Ann Surg Oncol 21:3256–3260

38. Lee JM, Georgian-Smith D, Gazelle GS et al (2008) Detecting nonpalpable recurrent breast cancer: the role of routine mammographic screening of transverse rectus abdominis myocutaneous flap reconstructions. Radiology 248:398–405

39. Lee JM, Georgian-Smith D, Gazelle GS et al (2008) Detecting nonpalpable recurrent breast cancer: the role of routine mammographic screening of transverse rectus abdominis myocutaneous flap reconstructions. Radiology 248:398–405

40. Lam DL, Houssami N, Lee JM (2017) Imaging surveillance after primary breast cancer treatment. AJR Am J Roentgenol 208:676–686

41. Sia J, Moodie K, Bressel M et al (2016) A prospective study comparing digital breast tomosynthesis with digital mammography in surveillance after breast cancer treatment. Eur J Cancer 61:122–127

42. Berg WA, Zhang Z, Lehrer D et al (2012) Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA 307:1394–1404

43. Sardaneli F, Boetes C, Borisch B et al (2010) Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer 46:1296–1316

44. Weinstock C, Campassi C, Goloubeva O et al (2015) Breast magnetic resonance imaging (MRI) surveillance in breast cancer survivors. Springerplus 4:459

45. Lehman CD, Lee JM, DeMartini WB et al (2016) Screening MRI in women with a personal history of breast cancer. J Natl Cancer Inst 108:djv349

46. Cho N, Han W, Han BK et al (2017) Breast cancer screening with mammography plus ultrasonography or magnetic resonance imaging in women 50 years or younger at diagnosis and treated with breast conservation therapy. JAMA Oncol 3:1495–1502

47. Houssami N, Abraham LA, Kerlikowske K et al (2013) Risk factors for second screen-detected or interval breast cancers in women with a personal history of breast cancer participating in mammography screening. Cancer Epidemiol Biomarkers Prev 22:946–961

48. Witteveen A, Vliegen IM, Sonke GS, Klaase JM, Izerman MJ, Stiensling S (2015) Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients. Breast Cancer Res Treat 152:627–636

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.